Search Results - linda+smith+resar

3 Results

Sort By:

Gene silencing technology for the treatment of triple negative breast cancer

Invention Novelty: The given invention proposes an efficient technology for the treatment of triple negative breast cancer Value Proposition: Often associated with rapid progression and poor outcomes, Triple Negative Breast Cancer (TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR)...

Published: 10/3/2024 | Inventor(s): Leslie Cope, David Huso, Linda Smith Resar

Keywords(s): Biomarker, Breast Cancer, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Women's Health, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

HMG-1 transgenic mouse

C04452: HMG-1 transgenic mouse Technical Details: The HMG-I/Y gene is overexpressed in human cancer, although a direct role for this gene in transformation had not been established. JHU researchers have generated transgenic mice with HMG-I targeted to lymphoid cells. All 7 informative founder HMG-I mice developed aggressive lymphoma by a mean age...

Published: 10/3/2024 | Inventor(s): Linda Smith Resar

Keywords(s): Cancers, Discovery/Research Tools, Disease Indication, In Vivo Research Tool, Mouse Model, Mouse Model Xenograft, Translational Research Biomarker

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools

A p105-based NF-(kappa) B Super repressor

C04290: A p105-based NF-(kappa) B Super repressor Technical Details: Nuclear factor (NF)-kB is a family of transcription factors that regulate immune and inflammatory responses, programmed cell death (apoptosis), and developmental processes. In normal cells, NF-kB is latent, and is activated transiently by stimuli and stresses. However, under pathological...

Published: 10/3/2024 | Inventor(s): Li Lin

Keywords(s): Biologics, Cancers, Chemotherapy, Disease Indication, Nucleic Acid, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities